Iberdomide not checked
Celgene · CC-220 · BMS-986382
FollowEvery change as it happens, and a Monday email
Trials
12 active
19 in total · 11 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.”In the company’s words, NCT02773030 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (4 trials), Lymphoma, B-Cell
- Main trialPhase 3
- “This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).”In the company’s words, NCT04975997 on ClinicalTrials.gov
- Other names
- CC-220 · BMS-986382
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up4
- 16 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Aug 2028Phase 1 trial completes · ClinicalTrials.gov
- 1 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- 15 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 16 Nov 2027 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | |
| Phase 3Active, not recruiting | 15 Mar 2029 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | |
| Phase 1/2Active, not recruiting | 9 May 2024 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | |
| Phase 1Recruiting | 1 Aug 2028 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 1Active, not recruiting | 1 Dec 2028 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | |
| Phase 2Completed | 3 Aug 2021 | A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus | |
| Phase 1/2Completed | 15 Feb 2023 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | |
| Phase 1/2Withdrawn | 8 Apr 2026 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | |
| Phase 1Completed | 23 Jan 2023 | Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function | |
| Phase 1Terminated | 31 Jan 2023 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | |
| Phase 1Completed | 6 Jul 2023 | A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants | |
| Phase 1Terminated | 25 Apr 2025 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma | |
| Phase 3Authorised | not given | A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial) | |
| Phase 2Authorised | not given | ICON study: A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd) | |
| Phase 2Authorised | not given | Phase II study of iberdomide (CC220) maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients | |
| Phase 3Authorised | not given | MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM | |
| Phase 2Authorised | not given | A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse | |
| Phase 3Authorised | not given | GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D. | |
| Phase 2Authorised | not given | Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026